Sign in

    Steve Ledger

    Chief Executive Officer at Serina Therapeutics Inc
    Board
    Since March 2024
    Age
    65 years
    Education
    Holds a Bachelor of Arts in Economics from the University of Connecticut.
    Tenure
    Joined SER in June 2021 as the Chief Financial Officer, became a board member in December 2022, and was promoted to Interim Chief Executive Officer in March 2024, later confirmed as CEO.

    Also at Serina Therapeutics Inc

    BSG
    Balkrishan Simba Gill
    Executive Chairman of the Board of Directors
    GSC
    Gregory S. Curhan
    Chief Financial Officer
    RM
    Randall Moreadith
    Chief Development Officer

    About

    Steve Ledger is a seasoned executive with a strong background in finance and economics, evidenced by his educational achievements, including a Bachelor of Arts in Economics from the University of Connecticut.

    He began his career in leadership roles at early-stage companies and later transitioned to significant advisory and operating positions. His multifaceted experience includes founding and managing investment firms as well as advising on value-based equity and debt securities.

    At SER, his tenure began in June 2021 as the Chief Financial Officer, progressing to a board member role in December 2022. In March 2024, he was appointed Interim Chief Executive Officer and later confirmed as the permanent CEO, demonstrating his ability to drive strategic growth during transitional phases.

    With over 35 years of experience in investment, board service, and operational leadership, his career reflects a commitment to both financial rigor and socially responsible initiatives, positioning him as a pivotal figure within the organization.

    $SER Performance Under Steve Ledger

    Past Roles

    OrganizationRoleDate RangeDetails
    Serina Therapeutics (SER) Interim Chief Executive Officer March 2024 - September 2024 Held interim role before permanent CEO appointment
    Serina Therapeutics (SER) Chief Financial Officer June 2021 - March 2024 Preceded his CEO role
    Caldwell Sutter Capital, Inc. Advisor 2018 - February 2022 SEC-registered broker-dealer and investment management firm
    Tamalpais Partners, LLC Founder and Managing Member 2002 - 2012 General partner to funds focused on special situations in small cap public equity markets

    External Roles

    OrganizationRoleDate RangeDetails
    Entourage Genomics, Inc. Co-founder and Board Director June 2023 - present Bioinformatics software company formed by FFV
    Form & Fiction Ventures, Inc. Managing Partner 2018 - present Venture studio launching and investing in startup & seed-stage companies focused on socially responsible initiatives

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Annual Base Salary$450,000 AnnualEstablished in the Ledger Employment Agreement
    Option Awards376,388 shares Vesting: 25% after 12 months; 36 monthly installmentsExercise Price: $7.40 per share; Grant Date: September 9, 2024
    Termination Benefits$450,000 + $112,500 Upon termination without cause12 months base salary plus pro-rated bonus (minimum of half the annual bonus)

    Performance Compensation

    Data from  FY 2024

    Annual Incentive Bonus

    ParameterDetail
    Eligible Bonus Amount$225,000 (50% of a $450,000 base salary)
    Actual Payout$144,949
    Performance MetricsNot provided
    Evaluation Period2024

    Performance Option Awards

    ParameterDetail
    Granted Shares125,463 shares
    Vesting Schedule25% vests after 12 months; remaining 75% vests in 36 monthly installments contingent upon strategic goals
    Exercise Price$7.40 per share
    Performance MetricsNot provided

    One-time Cash Bonus

    ParameterDetail
    Award AmountNot specified
    ConditionContingent upon attainment of certain strategic goals
    Performance MetricsNot provided